Percentage of non-small cell lung cancer (NSCLC) surgical pathology reports that include epidermal growth factor receptor (EGFR) mutation status. INSTRUCTIONS: This measure is to be reported each time a non-small cell lung cancer specimen pathology report is finalized during the performance period. This measure may be submitted by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. The results of EGFR testing of a specimen are frequently needed at some point during a patient’s treatment. Pathologists are uniquely well positioned at the time of signing out the surgical pathology report to detail the disposition of EGFR testing for that specimen. A significant number of patients with early-stage disease will progress to advanced disease in which EGFR mutation results can eventually guide their therapy. Referring physicians depend on both the pathologists’ interpretations of and any recommendations for tests in order to provide quality patient care. If the status is not indicated in each pathology report for the patient, unnecessary repeat testing may be performed delaying treatment and increasing cost. This measure monitors the success of pathologists in effectively communicating this important information for the purpose of care coordination and efficient use of resources.